ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Pier Luigi Luigi ZinzaniJiří MayerChristopher R FlowersFontanet BijouAna C OliveiraYuqin SongQingyuan ZhangMichele MerliKrimo BouabdallahPeter GanlyHuilai ZhangRoderick JohnsonAlejandro Martin Martin Garcia-SanchoMariano Provencio PullaMarek TrněnýSam YuenHerve TillyEdwin KingsleyGayane TumyanSarit E AssoulineRebecca AuerElena IvanovaPil KimSha HuangRichard DelarueJudith TrotmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The combination of ZO met its primary endpoint of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.